Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Caribou Biosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 113 | 133 | +20 |
| Shares | 43.2M | 43.6M | +358.9K (+0.8%) |
| Value | $456.8M | $273.8M | −$183.0M (−40.1%) |
New holders (30)
Institutions that held Caribou Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (10)
Institutions that held Caribou Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Farallon Capital Management, L.L.C. | 896,369 | $9.46M |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 271,430 | $2.86M |
| BNP Paribas Arbitrage, SA | 83,101 | $876.7K |
| Bellevue Group AG | 66,300 | $699.0K |
| Kettle Hill Capital Management, LLC | 37,200 | $392.0K |
| Occudo Quantitative Strategies LP | 20,394 | $215.0K |
| Virtu Financial LLC | 20,067 | $212.0K |
| Jane Street Group, LLC | 17,313 | $183.0K |
| Schonfeld Strategic Advisors LLC | 15,344 | $162.0K |
| Castle Wealth Management LLC | 500 | $5.00K |